KSTP-TV13h
Patients could get at-home flu vaccine as early as next year
But next year, you could get vaccinated for the flu at home. Just last month, the FDA approved FluMist, a nasal-spray flu ...
CNET18h
Still Need a Flu Vaccine? Now May Be a Good Time to Get One
Protection from shots like the flu vaccine typically takes a couple of weeks to kick in, so getting one now may offer ...
Needle-free influenza vaccine on the horizon
Hope is on the horizon for needle-phobic patients as Griffith University researchers have created a new influenza vaccine ...
JD Supra5d
FDA Approves the First Flu Vaccine for At Home Use, Providing a Needle Free Option Outside of Traditional Health Care Settings
On September 20, 2024, the U.S. Food and Drug Administration (FDA) approved the first influenza (flu) vaccine for at‑home use. The vaccine, ...
Money Talks News on MSN6d
No Doctor Needed: FDA Greenlights Self-Administered Flu Vaccine
This nasal spray vaccine can be self-administered or given by a caregiver, potentially increasing vaccination rates and ...
Yahoo Finance15d
AuraVax Therapeutics awarded contract from BARDA to evaluate NanoSTING platform as mucosal adjuvant for intranasal pandemic influenza vaccine
Codagenix is investigating intranasal LAIV as a candidate for a pandemic influenza vaccine. The two companies will test adjuvanted intranasal LAIV to assess activity against H5N1, the highly ...
The Victoria Advocate16d
AuraVax Therapeutics awarded contract from BARDA to evaluate NanoSTING platform as mucosal adjuvant for intranasal pandemic influenza vaccine
AuraVax will evaluate its novel mucosal adjuvant (NanoSTING-002) in combination with live attenuated influenza virus (LAIV). Intranasal NanoSTING-002 delivers a STING agonist to improve the ...
BioSpace16d
AuraVax Therapeutics awarded contract from BARDA to evaluate NanoSTING platform as mucosal adjuvant for intranasal pandemic influenza vaccine
Codagenix is investigating intranasal LAIV as a candidate for a pandemic influenza vaccine. The two companies will test adjuvanted intranasal LAIV to assess activity against H5N1, the highly ...
Mena FN17d
Bluewillow Biologics To Present Significant Progress On Its Novel Intranasal Vaccine Technology At World Vaccine Congress Europe
The presentation will also explore the platform's potential to broadly reshape the landscape of intranasal vaccines, particularly targeting influenza (pandemic and seasonal), tuberculosis ...